Managing Oncologic Emergencies

---
name: managing-oncologic-emergencies
language: en
description: Guides recognition and management of spinal cord compression, tumor lysis, SVC syndrome, and hypercalcemia. Use when managing oncologic emergencies, treating tumor lysis, or recognizing cord compression.
tags:
  - management
  - oncology
metadata:
  author: casemark
  practice_areas:
    - Medical Oncology
    - Hematology-Oncology
    - Radiation Oncology
  document_types:
    - Management Report
  skill_modes:
    - Management
    - Coordination
---

# Managing Oncologic Emergencies

Guides recognition and management of spinal cord compression, tumor lysis, SVC syndrome, and hypercalcemia.

## Why This Skill Exists

Oncologic emergencies are acute, life-threatening conditions caused by cancer or its treatment that require immediate recognition and intervention. Delayed treatment of spinal cord compression by even hours can result in permanent paraplegia. Unrecognized tumor lysis syndrome leads to fatal cardiac arrhythmia from hyperkalemia. Malignant hypercalcemia untreated progresses to coma and death. SVC syndrome, while rarely immediately fatal, causes significant morbidity and may indicate a tissue diagnosis emergency.

Emergency department physicians, oncologists, and hospitalists must be able to rapidly recognize these conditions and initiate treatment per evidence-based protocols. NCCN guidelines, ASCO emergency management resources, and institutional rapid response protocols provide the framework. Documentation of timely recognition and intervention is critical for quality metrics, medicolegal protection, and outcomes reporting.

---

## Checkpoint A: Pre-Draft Intake (Mandatory)

1. Which oncologic emergency is suspected or confirmed? (Default: identify specific emergency)
2. What is the underlying cancer diagnosis and stage? (Default: [VERIFY])
3. What are the presenting symptoms and their onset timeline? (Default: document)
4. What is the patient's current performance status and overall prognosis? (Default: assess)
5. What is the patient's code status and advance directive? (Default: verify — affects management aggressiveness)
6. What labs have been obtained (BMP, calcium, phosphorus, uric acid, LDH, CBC)? (Default: STAT labs)
7. What imaging has been obtained or is pending? (Default: document)
8. What cancer-directed treatment is the patient currently receiving? (Default: specify)

### Documents to Request

- STAT laboratory results (BMP, ionized calcium, phosphorus, uric acid, LDH, CBC)
- Urgent imaging (MRI spine for cord compression, CT chest for SVC syndrome)
- Current medication list
- Cancer treatment history and current regimen
- Advance directive and code status documentation
- Most recent imaging showing disease extent
- Prior radiation fields if considering emergent radiation
- EKG if cardiac arrhythmia risk (hypercalcemia, hyperkalemia)

---

## Step 1: Recognize the Oncologic Emergency

**Malignant Spinal Cord Compression (MSCC):**
- **Presentation:** Back pain (90% of cases, often preceding neurologic deficits by weeks), weakness, sensory level, urinary retention, saddle anesthesia
- **High-risk cancers:** Lung, breast, prostate, renal cell, myeloma
- **Critical time:** Neurologic function at time of treatment initiation predicts outcome — ambulatory patients who receive treatment within 24 hours have >80% chance of remaining ambulatory. Non-ambulatory patients have <30% chance of recovering ambulation.
- **Diagnostic:** MRI entire spine (not just symptomatic level — 10% have multiple levels of compression)

**Tumor Lysis Syndrome (TLS):**
- **Laboratory TLS (Cairo-Bishop criteria):** ≥2 of the following within 3 days before or 7 days after treatment: uric acid ≥8 mg/dL (or 25% increase), potassium ≥6 mEq/L (or 25% increase), phosphorus ≥4.5 mg/dL (or 25% increase), calcium ≤7 mg/dL (or 25% decrease)
- **Clinical TLS:** Laboratory TLS + renal insufficiency (creatinine ≥1.5× ULN), cardiac arrhythmia, seizure, or death
- **High-risk:** Burkitt lymphoma, ALL with WBC >100K, DLBCL with bulky disease, rapid tumor lysis with venetoclax

**Superior Vena Cava (SVC) Syndrome:**
- **Presentation:** Facial/upper extremity edema, dyspnea, cough, head fullness worse when supine, dilated chest wall veins
- **High-risk cancers:** Lung cancer (most common cause), lymphoma, mediastinal germ cell tumors
- **Diagnostic:** CT chest with contrast; avoid upper extremity IV contrast on affected side

**Malignant Hypercalcemia:**
- **Presentation:** Confusion, polyuria, constipation, nausea, weakness, shortened QTc, coma
- **Mechanism:** PTHrP-mediated (most common), osteolytic metastases, calcitriol-mediated (lymphoma), ectopic PTH (rare)
- **Threshold:** Corrected calcium >14 mg/dL or symptomatic at any level = emergency

---

## Step 2: Initiate Emergency Management

**MSCC — Treat within hours:**
1. Dexamethasone 10mg IV bolus immediately, then 4mg IV q6h
2. MRI entire spine — STAT (within 4 hours of presentation)
3. Radiation oncology consultation STAT — external beam RT is first-line for most cases (30 Gy/10 fractions or 20 Gy/5 fractions)
4. Surgical consultation if: unknown primary (tissue needed), spinal instability (SINS score ≥7), single level compression amenable to decompression, radiation-resistant histology (renal cell, melanoma), progression during/after radiation
5. Maintain spinal precautions until stability assessed
6. Foley catheter for urinary retention

**TLS — Prevention and treatment:**
1. **High-risk patients:** Rasburicase 0.2 mg/kg IV single dose (contraindicated in G6PD deficiency); aggressive IV hydration (3 L/m²/day NS); do NOT give allopurinol with rasburicase
2. **Intermediate-risk:** Allopurinol 300–600mg/day PO starting 1–2 days before treatment; IV hydration 2.5–3 L/m²/day
3. **Active TLS treatment:** Rasburicase for uric acid; IV calcium gluconate for symptomatic hypocalcemia or cardiac arrhythmia; insulin + glucose and/or sodium polystyrene for hyperkalemia; dialysis for refractory electrolyte derangement or oliguric renal failure
4. Monitor labs q6–8h during high-risk period

**SVC Syndrome:**
1. Elevate head of bed
2. If known NSCLC or solid tumor: urgent tissue diagnosis first (if safe), then radiation or stenting
3. If suspected lymphoma or germ cell tumor: biopsy first (chemoresponsive tumors — do not irradiate before tissue diagnosis)
4. If airway compromise: emergent SVC stenting by interventional radiology
5. Steroids (dexamethasone 4mg q6h) if airway edema or lymphoma suspected
6. Anticoagulation for associated thrombosis

**Malignant Hypercalcemia:**
1. IV normal saline 200–300 mL/hr (volume repletion is the most important first step)
2. Zoledronic acid 4mg IV over 15 minutes (onset 2–4 days, duration 4–6 weeks) OR denosumab 120mg SC (for renal insufficiency or bisphosphonate-refractory)
3. Calcitonin 4 IU/kg SC/IM q12h for rapid but temporary calcium lowering (bridge until bisphosphonate works)
4. Monitor calcium, creatinine, magnesium q12–24h
5. Do NOT use loop diuretics for hypercalcemia unless volume overloaded — this is outdated practice
6. Treat underlying cancer — hypercalcemia refractory to medical management without cancer treatment indicates poor prognosis

---

## Step 3: Monitor Response and Manage Complications

For each emergency, establish monitoring parameters:

| Emergency | Key Monitoring | Frequency | Escalation Trigger |
|-----------|---------------|-----------|-------------------|
| MSCC | Neurologic exam (motor, sensory, sphincter) | q4–6h during first 48h | New deficit or worsening = repeat MRI, surgical reassessment |
| TLS | BMP, uric acid, phosphorus, calcium, LDH | q6–8h × 48–72h | Potassium >6.5, creatinine rising, symptomatic hypocalcemia = ICU |
| SVC | Respiratory status, O2 saturation, facial edema | q4–6h | Worsening dyspnea or stridor = emergent stenting |
| Hypercalcemia | Corrected calcium, creatinine, mental status | q12–24h | Calcium not declining after 48h = denosumab or dialysis |

Document response to treatment, time to symptom improvement, and any treatment-related complications.

---

## Step 4: Document the Emergency and Disposition

Complete documentation for each oncologic emergency includes:

1. **Time of recognition** — document when the emergency was identified
2. **Time to first intervention** — critical quality metric (especially for MSCC — dexamethasone should be given within 1 hour of diagnosis)
3. **Diagnostic workup** with results and timeline
4. **Treatment administered** with doses, routes, and times
5. **Response assessment** with clinical and laboratory parameters
6. **Specialty consultations** obtained (radiation oncology, surgery, IR, ICU)
7. **Goals of care discussion** — oncologic emergencies often prompt reassessment of treatment goals, especially in advanced disease
8. **Disposition plan** — ICU admission, oncology floor, outpatient follow-up, or hospice referral if appropriate

---

## Checkpoint B: Post-Draft Alignment (Mandatory)

1. Was the emergency recognized and treated within the target timeframe (MSCC: dexamethasone within 1 hour; TLS: prevention initiated before treatment)?
2. Is the management algorithm followed per NCCN/ASCO guidelines for the specific emergency?
3. Were appropriate specialty consultations obtained (radiation oncology for MSCC, IR for SVC stenting)?
4. Is the monitoring plan documented with specific parameters, frequency, and escalation triggers?
5. Were goals of care discussed in the context of the emergency, particularly for patients with advanced disease?

---

## Quality Audit

- [ ] Oncologic emergency correctly identified with diagnostic criteria documented
- [ ] Time of recognition and time to first intervention documented
- [ ] MSCC: dexamethasone given within 1 hour of diagnosis
- [ ] MSCC: MRI entire spine obtained (not just symptomatic level)
- [ ] TLS: Cairo-Bishop criteria applied for grading (laboratory vs. clinical TLS)
- [ ] TLS: Risk stratification performed before chemotherapy initiation
- [ ] TLS: Rasburicase G6PD status checked before administration
- [ ] SVC: Tissue diagnosis obtained before radiation for suspected lymphoma/germ cell
- [ ] Hypercalcemia: IV hydration initiated before bisphosphonate
- [ ] Monitoring parameters and frequency documented
- [ ] Specialty consultations documented with recommendations
- [ ] Goals of care discussion documented
- [ ] Disposition plan documented with follow-up
- [ ] Communication to primary oncologist documented

---

## Guidelines

- MSCC is a time-critical emergency — dexamethasone should be administered within 1 hour of clinical suspicion, before MRI confirmation
- Always image the entire spine for suspected MSCC — multilevel disease is present in 10–38% of cases
- Do NOT use loop diuretics as first-line treatment for hypercalcemia — aggressive IV hydration with saline is the correct first step
- Rasburicase is contraindicated in G6PD deficiency — check G6PD status before administration. Rasburicase falsely lowers uric acid levels in samples left at room temperature — send lab samples on ice.
- TLS prevention is far more effective than treatment — risk-stratify every patient starting chemotherapy for hematologic malignancies
- SVC syndrome is rarely a true emergency requiring immediate intervention — obtain tissue diagnosis before treatment for chemoresponsive tumors (lymphoma, germ cell)
- Goals of care discussions are essential during oncologic emergencies — aggressive management of an emergency in a patient with end-stage disease may not align with patient values
- Document the timeline meticulously — time to intervention is a key quality metric and medicolegal consideration